Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by Pharmacia & ... receptor agonist which effectively reduces intraocular pressure. As ... latanoprost (under the trade name of Xalatan) entered ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Tobramycin Market, 2015-2019 2China Latanoprost Market Investigation Report 2015-2019 2
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has ... the college expand its reach and impact through innovative technologies and strategies. , “I ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... On Saturday, ... Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program titled ... 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... may extend and improve the lives of patients, according to a newly published ... here to read the full article. , The authors of the new ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... ANGELES (May 5, 2010) High doses of antioxidant ... genetic abnormalities in cells, which may predispose supplement-takers to developing ... Institute. The study, led by Eduardo Marbn, ... online today in the medical journal Stem Cells . ...
... ... launches their professional organization business specializing in all areas of the home. ... (PRWEB) ... market this month. The company’s mission is to create fabulous homes through ...
... stroke , TUESDAY, May 4 (HealthDay News) -- Being ... attack or stroke in men older than 45, a new ... ages 45 to 69, who enrolled in the California Men,s ... followed until Dec. 31, 2007. , During the follow-up, there ...
... experts say , TUESDAY, May 4 (HealthDay News) -- While rates ... the United States, a new study finds that among young, white ... of lower stomach cancer is infection with the bacteria Helicobacter ... by acid reflux. Most stomach cancers are found in those aged ...
... works in different fashion than the current widely accepted ... of the drugparticularly in people with cancer and diseases ... (LAM). The results of this study, led ... Diseases Institute, are published in the May 5 edition ...
... A medication most often used to treat heart arrhythmias also ... type of muscular dystrophy in adults. The findings about ... were published May 4 in the journal Neurology , ... there is no drug approved to treat myotonic dystrophy, an ...
Cached Medicine News:Health News:High doses of antioxidant supplements induce stem cell genetic abnormalities 2Health News:Stomach Cancer on the Rise Among Young, White Adults 2Health News:Stomach Cancer on the Rise Among Young, White Adults 3Health News:Popular diabetes drug works differently than thought 2Health News:Heart drug effective for treating symptom of muscular dystrophy 2Health News:Heart drug effective for treating symptom of muscular dystrophy 3
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
... The MonoPrep LBP Processor is a primary ... specimen collection, accessioning, processing, sampling, and slide ... data management. The MonoPrep LBP Processor produces ... from a broad range of cytology specimen ...
Medicine Products: